DK1223964T3 - APRIL-receptor og anvendelser deraf - Google Patents

APRIL-receptor og anvendelser deraf

Info

Publication number
DK1223964T3
DK1223964T3 DK00968780T DK00968780T DK1223964T3 DK 1223964 T3 DK1223964 T3 DK 1223964T3 DK 00968780 T DK00968780 T DK 00968780T DK 00968780 T DK00968780 T DK 00968780T DK 1223964 T3 DK1223964 T3 DK 1223964T3
Authority
DK
Denmark
Prior art keywords
april
april receptor
receptor
antibodies
methods
Prior art date
Application number
DK00968780T
Other languages
Danish (da)
English (en)
Inventor
Pascal Schneider
Jeffrey Thompson
Christine Ambrose
Teresa Cachero
Paul Rennert
Original Assignee
Biogen Idec Inc
Apotech R & D Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27388102&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1223964(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Idec Inc, Apotech R & D Sa filed Critical Biogen Idec Inc
Application granted granted Critical
Publication of DK1223964T3 publication Critical patent/DK1223964T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK00968780T 1999-10-06 2000-10-05 APRIL-receptor og anvendelser deraf DK1223964T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US15793399P 1999-10-06 1999-10-06
US18180700P 2000-02-11 2000-02-11
US21568800P 2000-06-30 2000-06-30
PCT/US2000/027579 WO2001024811A1 (en) 1999-10-06 2000-10-05 April receptor (bcma) and uses thereof

Publications (1)

Publication Number Publication Date
DK1223964T3 true DK1223964T3 (da) 2007-08-27

Family

ID=27388102

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00968780T DK1223964T3 (da) 1999-10-06 2000-10-05 APRIL-receptor og anvendelser deraf

Country Status (30)

Country Link
US (1) US7276241B2 (cs)
EP (3) EP1223964B1 (cs)
JP (2) JP4880155B2 (cs)
KR (1) KR100759295B1 (cs)
CN (1) CN1263507C (cs)
AT (1) ATE360434T1 (cs)
AU (1) AU776852B2 (cs)
BG (1) BG65473B1 (cs)
BR (1) BR0014583A (cs)
CA (1) CA2386463C (cs)
CZ (1) CZ297633B6 (cs)
DE (1) DE60034586T2 (cs)
DK (1) DK1223964T3 (cs)
EA (1) EA005601B1 (cs)
EE (1) EE05212B1 (cs)
GE (1) GEP20043375B (cs)
HK (1) HK1044710B (cs)
HU (1) HUP0203567A2 (cs)
IL (3) IL148839A0 (cs)
IS (1) IS6322A (cs)
MX (1) MXPA02003393A (cs)
NO (1) NO331683B1 (cs)
NZ (1) NZ517907A (cs)
PL (1) PL204010B1 (cs)
RS (1) RS51602B (cs)
SK (1) SK286331B6 (cs)
TR (1) TR200200912T2 (cs)
UA (1) UA74798C2 (cs)
WO (1) WO2001024811A1 (cs)
ZA (1) ZA200202578B (cs)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7217788B2 (en) 1996-03-14 2007-05-15 Human Genome Sciences, Inc. Human tumor necrosis factor delta polypeptides
US6541224B2 (en) 1996-03-14 2003-04-01 Human Genome Sciences, Inc. Tumor necrosis factor delta polypeptides
US8212004B2 (en) 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
DK1086223T3 (da) 1998-06-01 2009-11-30 Agensys Inc Nye serpentintransmembranantigener udtrykt i humane cancerformer og anvendelser deraf
GB9828628D0 (en) 1998-12-23 1999-02-17 Glaxo Group Ltd Novel ligand
WO2002094852A2 (en) 2001-05-24 2002-11-28 Zymogenetics, Inc. Taci-immunoglobulin fusion proteins
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
US20030095967A1 (en) * 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
US20050100548A1 (en) * 2001-07-24 2005-05-12 Biogen Idec Ma Inc. BAFF, inhibitors thereof and their use in the modulation of B-cell response
SK288603B6 (sk) 1999-08-17 2018-10-01 Biogen Ma Inc. Polypeptid a protilátka viažuca sa na polypeptid
AU2048501A (en) * 2000-02-16 2001-08-27 Genentech Inc. Uses of agonists and antagonists to modulate activity of tnf-related molecules
US20040002068A1 (en) * 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US7371388B1 (en) 2000-05-04 2008-05-13 Human Genome Sciences, Inc. Treatment of Sjogren's syndrome by administration of TR18 polypeptides
AU2001263114A1 (en) * 2000-05-12 2001-11-26 Amgen Inc Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
EP2281843B1 (en) * 2000-06-16 2016-10-12 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to BLyS
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
AU2001288301A1 (en) 2000-08-18 2002-03-04 Human Genome Sciences, Inc. Binding polypeptides and methods based thereon
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
AU2002311976A1 (en) * 2001-05-24 2002-12-03 Human Genome Sciences, Inc. Antibodies against tumor necrosis factor delta (april)
HUP0500992A3 (en) * 2001-08-03 2007-11-28 Genentech Inc Tacis and br3 polypeptides and uses thereof
US7494646B2 (en) 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
WO2003068977A2 (de) 2002-02-10 2003-08-21 Apoxis Sa Fusionkonstrukte, enthaltend aktive abschnitte von tnf-liganden
US20080267965A1 (en) * 2002-02-21 2008-10-30 Kalled Susan L Use of Bcma as an Immunoregulatory Agent
JP2005533863A (ja) * 2002-07-25 2005-11-10 ジェネンテック・インコーポレーテッド Taci抗体とその用途
CA2520097C (en) 2003-03-28 2014-10-07 Biogen Idec Ma Inc. Truncated baff receptors
PL1631313T3 (pl) * 2003-06-05 2015-08-31 Genentech Inc Terapia skojarzona zaburzeń z komórek B
US20050163775A1 (en) * 2003-06-05 2005-07-28 Genentech, Inc. Combination therapy for B cell disorders
EP1675609A1 (en) 2003-10-20 2006-07-05 Biogen Idec MA Inc. Therapeutic regimens for baff antagonists
PT1742966E (pt) 2004-04-22 2014-02-05 Agensys Inc Anticorpos e moléculas derivadas daí que se ligam às proteínas steap-1
CN1786016B (zh) * 2004-12-09 2010-12-29 中国人民解放军军事医学科学院基础医学研究所 一种人工构建的生物活性分子及其制备方法
EP1836224A1 (en) * 2004-12-23 2007-09-26 Laboratoires Serono S.A. Bcma polypeptides and uses thereof
DE602006007323D1 (de) * 2005-01-28 2009-07-30 Biogen Idec Inc VERWENDUNG VON BAFF ZUR BEHANDLUNG Th2-INDUZIERTER LEIDEN
KR20080056714A (ko) 2005-08-09 2008-06-23 지모제넥틱스, 인코포레이티드 TACI―Ig 융합 분자를 사용하여 B―세포 악성종양을치료하는 방법
CA2618763A1 (en) 2005-08-09 2007-02-15 Zymogenetics, Inc. Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
JP5905184B2 (ja) 2005-10-13 2016-04-20 ヒューマン ジノーム サイエンシーズ, インコーポレイテッドHuman Genome Sciences, Inc. 自己抗体陽性疾患を有する患者の処置に使用するための方法および組成物
WO2007062090A2 (en) 2005-11-23 2007-05-31 Genentech, Inc. Methods and compositions related to b cell assays
WO2007123765A2 (en) 2006-03-31 2007-11-01 Human Genome Sciences Inc. Neutrokine-alpha and neutrokine-alpha splice variant
JP2009537563A (ja) 2006-05-15 2009-10-29 アレス トレーディング ソシエテ アノニム Taci融合分子を使用する自己免疫疾患を治療するための方法
EP2061814B1 (en) * 2006-10-27 2012-06-06 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
MD24Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului neinvaziv al glandei mamare
MD23Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului lobular in situ neinvaziv al glandei mamare
MD35Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de apreciere a riscului dezvoltării carcinomului neinvaziv in situ al glandei mamare
MD36Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului ductal in situ neinvaziv al glandei mamare
WO2011047121A1 (en) * 2009-10-14 2011-04-21 Schering Corporation April antagonists and methods of use
UA112434C2 (uk) 2011-05-27 2016-09-12 Ґлаксо Ґруп Лімітед Антигензв'язувальний білок, який специфічно зв'язується з всма
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對bcma之e3以及cd3的結合分子
WO2013171296A1 (en) 2012-05-16 2013-11-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Diagnostic and treatment of sarcoidosis
TW201425336A (zh) * 2012-12-07 2014-07-01 Amgen Inc Bcma抗原結合蛋白質
EP2762497A1 (en) 2013-02-05 2014-08-06 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
WO2014122144A1 (en) 2013-02-05 2014-08-14 Engmab Ag BISPECIFIC ANTIBODIES AGAINST CD3ε AND BCMA
EP2762496A1 (en) 2013-02-05 2014-08-06 EngMab AG Method for the selection of antibodies against BCMA
US9688767B2 (en) 2013-03-15 2017-06-27 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method of predicting survival time in myocardial infarction patients by measuring BAFF levels
NL2011406C2 (en) 2013-09-06 2015-03-10 Bionovion Holding B V Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides.
GB201317929D0 (en) * 2013-10-10 2013-11-27 Ucl Business Plc Chimeric antigen receptor
MY183189A (en) 2013-11-19 2021-02-18 Regeneron Pharma Non-human animals having a humanized a proliferation-inducing ligand gene
WO2016003876A1 (en) 2014-07-03 2016-01-07 Oklahoma Medical Research Foundation Treatment of multiple sclerosis and neuromyelitis optica
EP2982692A1 (en) 2014-08-04 2016-02-10 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
EP3023437A1 (en) 2014-11-20 2016-05-25 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
EP3029068A1 (en) 2014-12-03 2016-06-08 EngMab AG Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases
NL2014108B1 (en) 2015-01-09 2016-09-30 Aduro Biotech Holdings Europe B V Altered april binding antibodies.
EA202092435A3 (ru) 2015-08-03 2021-06-30 Энгмаб Сарл Моноклональные антитела против bcma
MY191325A (en) 2015-08-17 2022-06-15 Janssen Pharmaceutica Nv Anti-bcma antibodies, bispecific antigen binding molecules that bind bcma and cd3, and uses thereof
CN108473575B (zh) * 2015-11-13 2022-04-19 美国卫生和人力服务部 抗-bcma多肽和蛋白质
EP4285923A3 (en) 2015-11-25 2024-03-06 Visterra, Inc. Antibody molecules to april and uses thereof
IL260732B2 (en) 2016-02-17 2024-08-01 Seagen Inc Bcma antibodies and use of same to treat cancer and immunological disorders
JP7432363B2 (ja) 2016-06-21 2024-02-16 テネオバイオ, インコーポレイテッド Cd3結合抗体
EP4050034B1 (en) 2016-09-14 2024-05-08 TeneoOne, Inc. Cd3 binding antibodies
MX2019004621A (es) 2016-11-02 2019-11-28 Engmab Sarl Anticuerpo biespecifico contra bcma y cd3 y un farmaco inmunologico para uso combinado en el tratamiento del mieloma multiple.
US11434299B2 (en) 2016-12-21 2022-09-06 Teneobio, Inc. Anti-BCMA heavy chain-only antibodies
SG11201909218RA (en) 2017-04-03 2019-11-28 Hoffmann La Roche Antibodies binding to steap-1
CN110945026B (zh) 2017-06-20 2024-03-19 特纳奥尼股份有限公司 仅有重链的抗bcma抗体
US11970540B2 (en) 2017-06-20 2024-04-30 Teneobio, Inc. Anti-BCMA heavy chain-only antibodies
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
WO2019139987A1 (en) 2018-01-09 2019-07-18 Elstar Therapeutics, Inc. Calreticulin binding constructs and engineered t cells for the treatment of diseases
US12152073B2 (en) 2018-03-14 2024-11-26 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
JP7395508B2 (ja) 2018-05-16 2023-12-11 ヤンセン バイオテツク,インコーポレーテツド 癌を治療する方法及びt細胞リダイレクト治療薬の有効性を向上させる方法
AU2019277029C1 (en) 2018-06-01 2024-01-04 Novartis Ag Binding molecules against BCMA and uses thereof
CA3105448A1 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
WO2020018922A1 (en) 2018-07-20 2020-01-23 Teneobio, Inc. Heavy chain antibodies binding to cd19
SG11202109061YA (en) 2019-02-21 2021-09-29 Marengo Therapeutics Inc Multifunctional molecules that bind to t cell related cancer cells and uses thereof
SG11202108955QA (en) 2019-02-21 2021-09-29 Marengo Therapeutics Inc Antibody molecules that bind to nkp30 and uses thereof
PE20220142A1 (es) 2019-04-05 2022-01-27 Teneobio Inc Anticuerpos de cadena pesada que se unen al psma
EP3972998A1 (en) 2019-05-21 2022-03-30 Novartis AG Cd19 binding molecules and uses thereof
US11905326B2 (en) 2019-06-14 2024-02-20 Teneobio, Inc. Multispecific heavy chain antibodies binding to CD22 and CD3
EP4006055A4 (en) 2019-07-30 2023-07-19 Shanghai Hansoh Biomedical Co., Ltd. ANTI-BCMA ANTIBODIES, ANTIGEN-BINDING FRAGMENT THEREOF AND MEDICAL USE THEREOF
TW202330622A (zh) 2020-04-29 2023-08-01 美商泰尼歐生物公司 具有經修飾重鏈恆定區之多特異性重鏈抗體
JP7625007B2 (ja) 2020-04-29 2025-01-31 テネオバイオ, インコーポレイテッド 重鎖定常領域が修飾された多重特異性重鎖抗体
PH12022553023A1 (en) 2020-05-11 2024-03-04 Janssen Biotech Inc Methods for treating multiple myeloma
CN115996748A (zh) * 2020-05-29 2023-04-21 奇努克医疗公司 用APRIL结合抗体治疗IgA肾病的方法
KR20230038211A (ko) 2020-06-30 2023-03-17 테네오바이오, 인코포레이티드 Bcma에 결합하는 다중특이적 항체
CR20230398A (es) 2021-02-16 2023-11-15 Janssen Pharmaceutica Nv Anticuerpo triespecífico dirigido a bcma, gprc5d, y cd3
KR20240004462A (ko) 2021-04-08 2024-01-11 마렝고 테라퓨틱스, 인크. Tcr에 결합하는 다기능성 분자 및 이의 용도
TW202309522A (zh) 2021-05-11 2023-03-01 美商健生生物科技公司 用於監測復發性及/或難治性多發性骨髓瘤之治療的方法及組成物
CN118678963A (zh) 2021-08-11 2024-09-20 艾克索生物制药有限公司 使用sBCMA变体及其FC融合蛋白减少IgA、IgM和/或IgG的产生的方法
IL312503A (en) 2021-11-03 2024-07-01 Janssen Biotech Inc Methods of treating cancers and enhancing efficacy of bcmaxcd3 bispecific antibodies
TW202440636A (zh) 2023-03-21 2024-10-16 美商傳記55有限公司 Cd19/cd38多特異性抗體
WO2025134050A1 (en) 2023-12-21 2025-06-26 Janssen Biotech, Inc Trispecific antibody targeting bcma, gprc5d and cd3 for the treatment of multiple myeloma
WO2025134049A1 (en) 2023-12-21 2025-06-26 Janssen Biotech, Inc Trispecific antibody targeting bcma, gprc5d and cd3 for the treatment of al amyloidosis
WO2025174963A1 (en) 2024-02-16 2025-08-21 Kite Pharma, Inc. Systems, methods, and kits for generating and administering engineered t cells and cd38 targeting compounds as a combination therapy

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
US6218510B1 (en) * 1994-03-02 2001-04-17 Brigham & Woman's Hospital B7-1 and B7-2 polypeptides
WO1997033902A1 (en) 1996-03-14 1997-09-18 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
US6541224B2 (en) * 1996-03-14 2003-04-01 Human Genome Sciences, Inc. Tumor necrosis factor delta polypeptides
PT939804E (pt) 1996-10-25 2005-11-30 Human Genome Sciences Inc Neutroquina alfa
AU5705898A (en) 1996-12-17 1998-07-15 Schering Corporation Mammalian cell surface antigens; related reagents
US5969102A (en) * 1997-03-03 1999-10-19 St. Jude Children's Research Hospital Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
CA2232743A1 (en) 1997-04-02 1998-10-02 Smithkline Beecham Corporation A tnf homologue, tl5
CA2292835A1 (en) 1997-06-06 1998-12-10 Regeneron Pharmaceuticals, Inc. Ntn-2 member of tnf ligand family
IL133315A0 (en) 1997-06-06 2001-04-30 Regeneron Pharma Ntn-2 member of tnf ligand family
AU9376498A (en) 1997-09-05 1999-03-22 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
HUP0004034A3 (en) * 1997-09-12 2002-08-28 Apotech R & D Sa Kay - a novel immune system protein
CA2303615A1 (en) * 1997-09-12 1999-03-18 Jurg Tschopp April- a novel protein with growth effects
US6297367B1 (en) * 1997-12-30 2001-10-02 Chiron Corporation Polynucleotide encoding TNFL1
WO1999033980A2 (en) 1997-12-30 1999-07-08 Chiron Corporation Members of tnf and tnfr families
WO2000026244A2 (en) 1998-11-04 2000-05-11 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A novel tumor necrosis factor family member, drl, and related compositions and methods
GB9828628D0 (en) 1998-12-23 1999-02-17 Glaxo Group Ltd Novel ligand
DE60005135T3 (de) * 1999-01-07 2015-04-09 Zymogenetics, Inc. Lösliche rezeptoren br43x2 und verfahren zu deren therapeutischen verwendung
US20060067933A1 (en) * 1999-01-07 2006-03-30 Gross Jane A Soluble receptor BR43x2 and methods of using
CA2360062A1 (en) 1999-01-25 2000-07-27 Biogen, Inc. Baff, inhibitors thereof and their use in the modulation of b-cell response
US6475986B1 (en) * 1999-02-02 2002-11-05 Research Development Foundation Uses of THANK, a TNF homologue that activates apoptosis
NZ513290A (en) 1999-02-23 2004-05-28 Human Genome Sciences Inc Neutrokine-alpha and neutrokine-alpha splice variant
EP1157126A4 (en) * 1999-02-24 2005-03-02 Gen Hospital Corp METHOD FOR CLONING INTERMEDIATE SIGNAL TRANSDUCTION PRODUCTS
AU3633000A (en) 1999-03-26 2000-10-16 Human Genome Sciences, Inc. Neutrokine-alpha binding proteins and methods based thereon
AU4986700A (en) * 1999-05-06 2000-11-21 National Jewish Medical And Research Center Tall-1 nucleic acid molecules, proteins, receptors and methods of use thereof
SK288603B6 (sk) * 1999-08-17 2018-10-01 Biogen Ma Inc. Polypeptid a protilátka viažuca sa na polypeptid
NZ520789A (en) 2000-02-11 2005-01-28 Biogen Inc Heterologous polypeptide of the TNF family
AU2048501A (en) * 2000-02-16 2001-08-27 Genentech Inc. Uses of agonists and antagonists to modulate activity of tnf-related molecules
US20040013674A1 (en) 2001-04-27 2004-01-22 Christine Ambrose Taci as an anti-tumor agent
AU2001263114A1 (en) 2000-05-12 2001-11-26 Amgen Inc Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
EP2281843B1 (en) 2000-06-16 2016-10-12 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to BLyS
CA2419661A1 (en) 2000-08-15 2002-03-07 Guo-Liang Yu Neutrokine-alpha and neutrokine-alpha splice variant
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
EP1456347A4 (en) 2001-11-16 2006-08-02 Human Genome Sciences Inc ANTIBODIES BINDING TO BLYS ACCORDING TO AN IMMUNOSPECIFIC MODE

Also Published As

Publication number Publication date
CA2386463C (en) 2012-02-07
EE05212B1 (et) 2009-10-15
AU7864500A (en) 2001-05-10
EE200200181A (et) 2003-06-16
NZ517907A (en) 2004-01-30
JP2003510366A (ja) 2003-03-18
IL204401A (en) 2014-12-31
KR100759295B1 (ko) 2007-09-18
UA74798C2 (uk) 2006-02-15
PL355102A1 (en) 2004-04-05
EP2324844A2 (en) 2011-05-25
ZA200202578B (en) 2003-07-02
YU25302A (sh) 2005-06-10
DE60034586D1 (de) 2007-06-06
ATE360434T1 (de) 2007-05-15
EA200200427A1 (ru) 2002-12-26
BR0014583A (pt) 2002-06-11
BG65473B1 (bg) 2008-09-30
BG106670A (en) 2002-12-29
TR200200912T2 (tr) 2002-07-22
NO20021594L (no) 2002-06-05
KR20020053066A (ko) 2002-07-04
JP2011079863A (ja) 2011-04-21
HK1044710A1 (en) 2002-11-01
HK1044710B (en) 2007-12-07
WO2001024811A1 (en) 2001-04-12
SK4512002A3 (en) 2002-12-03
IS6322A (is) 2002-03-22
DE60034586T2 (de) 2008-02-28
CN1399556A (zh) 2003-02-26
US20030082175A1 (en) 2003-05-01
PL204010B1 (pl) 2009-12-31
HUP0203567A2 (hu) 2003-02-28
EP1847273A1 (en) 2007-10-24
AU776852B2 (en) 2004-09-23
EP1223964A1 (en) 2002-07-24
CA2386463A1 (en) 2001-04-12
EA005601B1 (ru) 2005-04-28
US7276241B2 (en) 2007-10-02
EP1223964B1 (en) 2007-04-25
IL148839A0 (en) 2002-09-12
JP4880155B2 (ja) 2012-02-22
RS51602B (sr) 2011-08-31
CN1263507C (zh) 2006-07-12
EP2324844A3 (en) 2013-12-11
NO20021594D0 (no) 2002-04-04
SK286331B6 (en) 2008-07-07
CZ20021169A3 (cs) 2002-09-11
GEP20043375B (en) 2004-11-25
IL148839A (en) 2015-01-29
CZ297633B6 (cs) 2007-02-14
MXPA02003393A (es) 2004-08-19
NO331683B1 (no) 2012-02-20

Similar Documents

Publication Publication Date Title
DK1223964T3 (da) APRIL-receptor og anvendelser deraf
SK500172015A3 (cs)
EP1151002A4 (en) KDR-SPECIFIC ANTIBODIES AND USES THEREOF
NO20020554D0 (no) Antistoff-molekyler med spesifisitet for human tumornekrosefaktor-alfa, og anvendelse derav
ATE278712T1 (de) Antikörper gegen plazentaprotein 13
KR960030206U (ko) 가방손잡이에 완충판의 결합구조
FI1829U1 (fi) Naturstenselement foer anvaendning i samband med vaermare
FIU950040U0 (fi) Naturstenselement foer anvaendning i samband med vaermare
SE9402150D0 (sv) Methods and means to obtain streptococcal proteins and the use of the genes encoding these proteins
KR970060448U (ko) 휴대용 물병의 흡입구 인출 장치
NO951061D0 (no) Antistoffkonjugater med forbedrede egenskaper
BR7601388U (pt) Sanitário portátil com saquinhos descartáveis
GB0024542D0 (en) Materials and methods relating to the use and production of novel antibody complexes